Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286999 | 0.81 | HSD17B10 (0.47) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL27432878 | 0.81 | HSD17B10 (0.47) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL3825943 | 0.81 | MAPT (0.38) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL5010822 | 0.79 | ALDH1A1 (0.43) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| Hydrochloric Acid SCHEMBL10496189 | 0.79 | HSD17B10 (0.46) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL210291 | 0.79 | HSD17B10 (0.50) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL20855357 | 0.78 | POLB (0.37) | ALDH1A1HPGDPOLBHTTTSHR | |
| SCHEMBL540823 | 0.77 | ALDH1A1 (0.45) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL1877975 | 0.77 | ALDH1A1 (0.53) | MAPTALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL18574305 | 0.77 | ALDH1A1 (0.42) | MAPTALDH1A1HSD17B10HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678468-B | 5, 6-fused bicyclic compounds and compositions thereof for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-4444728-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-11939343-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220324863-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | US | disclosed |
| CN-110678468-B | 5, 6-fused bicyclic compounds and compositions thereof for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| US-20220202815-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| CN-102007120-A | Fungicide hydroxyimino-heterocyclic derivatives | BAYER CROPSCIENCE AG | 2011-04-06 | — | — | CN | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | IL5, CYP3A5, ABCB11 | MAPT 3210/4885ALDH1A1 775/4885HSD17B10 763/4885 |
| US-11939343-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | MAPT 4779/4885ALDH1A1 4848/4885HSD17B10 4281/4885 |
| US-20220202815-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | MAPT 4700/4885ALDH1A1 3620/4885HSD17B10 3822/4885 |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | MAPT 590/4885ALDH1A1 1403/4885HSD17B10 2308/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | MAPT 4621/4885ALDH1A1 1278/4885HSD17B10 486/4885 |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | MAPT 590/4885ALDH1A1 1403/4885HSD17B10 2308/4885 |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | MAPT 570/4885ALDH1A1 1431/4885HSD17B10 2378/4885 |
| US-20220324863-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IL5, CYP3A5, ABCB11 | MAPT 3181/4885ALDH1A1 801/4885HSD17B10 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.